LT3004155T - Peptidų junginys - Google Patents
Peptidų junginysInfo
- Publication number
- LT3004155T LT3004155T LTEPPCT/JP2014/002772T LT14729976T LT3004155T LT 3004155 T LT3004155 T LT 3004155T LT 14729976 T LT14729976 T LT 14729976T LT 3004155 T LT3004155 T LT 3004155T
- Authority
- LT
- Lithuania
- Prior art keywords
- peptide compound
- peptide
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013111893 | 2013-05-28 | ||
PCT/JP2014/002772 WO2014192284A1 (en) | 2013-05-28 | 2014-05-27 | Peptide compound |
Publications (1)
Publication Number | Publication Date |
---|---|
LT3004155T true LT3004155T (lt) | 2021-12-27 |
Family
ID=50942304
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEPPCT/JP2014/002772T LT3004155T (lt) | 2013-05-28 | 2014-05-27 | Peptidų junginys |
Country Status (36)
Country | Link |
---|---|
US (2) | US9200051B2 (lt) |
EP (1) | EP3004155B1 (lt) |
JP (2) | JP6429799B2 (lt) |
KR (1) | KR102229051B1 (lt) |
CN (1) | CN105209485B (lt) |
AP (1) | AP2015008781A0 (lt) |
AR (1) | AR096440A1 (lt) |
AU (1) | AU2014272500B2 (lt) |
CA (1) | CA2908581C (lt) |
CL (1) | CL2015003031A1 (lt) |
CY (1) | CY1124790T1 (lt) |
DK (1) | DK3004155T3 (lt) |
DO (1) | DOP2015000261A (lt) |
EA (2) | EA035813B1 (lt) |
EC (1) | ECSP15044389A (lt) |
ES (1) | ES2900744T3 (lt) |
GE (1) | GEP201706762B (lt) |
HK (1) | HK1216757A1 (lt) |
HR (1) | HRP20212014T1 (lt) |
HU (1) | HUE057361T2 (lt) |
IL (1) | IL242005B (lt) |
LT (1) | LT3004155T (lt) |
MA (1) | MA38472B1 (lt) |
MX (2) | MX2015015464A (lt) |
MY (1) | MY172744A (lt) |
PE (1) | PE20151770A1 (lt) |
PH (1) | PH12015502391A1 (lt) |
PL (1) | PL3004155T3 (lt) |
PT (1) | PT3004155T (lt) |
SG (1) | SG11201507934PA (lt) |
SI (1) | SI3004155T1 (lt) |
TN (1) | TN2015000451A1 (lt) |
TW (1) | TWI638831B (lt) |
UA (1) | UA118558C2 (lt) |
UY (1) | UY35589A (lt) |
WO (1) | WO2014192284A1 (lt) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA38472B1 (fr) | 2013-05-28 | 2018-09-28 | Takeda Pharmaceuticals Co | Composé peptidique |
JOP20200119A1 (ar) * | 2015-01-09 | 2017-06-16 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
CN104846061A (zh) * | 2015-05-07 | 2015-08-19 | 中国药科大学 | 一种glp-1受体激动剂的受体亲和力测定方法 |
CN105388239B (zh) * | 2015-12-18 | 2018-01-05 | 兆科药业(合肥)有限公司 | 一种多肽固相合成的监测方法 |
CN109477094B (zh) * | 2016-05-24 | 2022-04-26 | 武田药品工业株式会社 | 肽化合物 |
WO2018104263A1 (en) | 2016-12-06 | 2018-06-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of enhancing the potency of incretin-based drugs in subjects in need thereof |
JOP20180028A1 (ar) | 2017-03-31 | 2019-01-30 | Takeda Pharmaceuticals Co | مركب ببتيد |
WO2019140030A1 (en) | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Combination therapy |
BR112020014596A2 (pt) | 2018-01-23 | 2020-12-08 | Gila Therapeutics, Inc. | Formulações, composições e métodos farmacêuticos de peptídeo yy |
TWI707865B (zh) * | 2018-05-04 | 2020-10-21 | 丹麥商諾佛 儂迪克股份有限公司 | Gip衍生物及其用途 |
CN110818771B (zh) * | 2018-08-14 | 2023-01-17 | 陈铭 | 使用氨基酸离子液体的羰基硫介导多肽合成 |
JP2022500483A (ja) * | 2018-09-24 | 2022-01-04 | 武田薬品工業株式会社 | Gip受容体アゴニストペプチド化合物及びその使用 |
US20220135638A1 (en) * | 2018-09-24 | 2022-05-05 | Takeda Pharmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
CA3148347A1 (en) * | 2019-08-19 | 2021-02-25 | Michael E. Kopach | Methods of making incretin analogs |
KR20210040818A (ko) | 2019-10-04 | 2021-04-14 | 한미약품 주식회사 | 글루카곤, 및 glp-1 수용체 및 gip 수용체 이중 작용제를 포함하는 조성물 및 이의 치료학적 용도 |
CN110684082B (zh) | 2019-10-08 | 2021-12-10 | 江苏诺泰澳赛诺生物制药股份有限公司 | Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途 |
CA3173129A1 (en) * | 2020-03-25 | 2021-09-30 | Antoine Charles Olivier HENNINOT | Qd dosing of gip receptor agonist peptide compounds and uses thereof |
CA3184717A1 (en) | 2020-07-22 | 2022-01-27 | Patrick J. KNERR | Co-agonists at glp-1 and gip receptors suitable for oral delivery |
JP2023534130A (ja) | 2020-07-22 | 2023-08-08 | ノヴォ ノルディスク アー/エス | Glp-1受容体およびgip受容体共作動薬 |
CA3222051A1 (en) | 2021-06-01 | 2022-12-08 | Nanjing Zhihe Medicine Technology Co., Ltd. | Polypeptide derivative having effect of dual targeted activation of glp-1r and gipr, preparation method therefor, and use thereof |
TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
CN117402219A (zh) * | 2022-07-13 | 2024-01-16 | 杭州中美华东制药有限公司 | Glp-1/gip双激动剂及其制备方法和用途 |
WO2024059674A1 (en) | 2022-09-15 | 2024-03-21 | Eli Lilly And Company | Gip and glp-1 dual agonist compounds |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
ES2237790T3 (es) | 1996-11-12 | 2005-08-01 | Novo Nordisk A/S | Uso de peptidos glp-1. |
AU3087599A (en) | 1998-03-19 | 1999-10-11 | Bionebraska, Inc. | Human appetite control by glucagon-like peptide receptor binding compounds |
EP1932535A3 (en) | 1998-07-31 | 2008-10-29 | Novo Nordisk A/S | Stimulation of beta cell profileration |
EP1992641A3 (en) | 1998-12-07 | 2009-07-29 | Ipsen Pharma | GLP-1 analogues |
EP1283058A4 (en) | 2000-05-16 | 2004-06-23 | Sanwa Kagaku Kenkyusho Co | AGENTS FOR PREVENTING OR IMPROVING INSULIN RESISTANCE AND / OR OBESITY |
DE60327771D1 (de) | 2002-07-04 | 2009-07-09 | Zealand Pharma As | Glp-1 und behandlungsmethode für diabetes |
US7897566B2 (en) | 2003-12-16 | 2011-03-01 | Ipsen Pharma S.A.S. | Analogues of GLP-1 |
WO2006049681A2 (en) | 2004-08-30 | 2006-05-11 | Bayer Pharmaceuticals Corporation | Selective neuropeptide y2 receptor agonists |
EP2392595A1 (en) | 2005-02-11 | 2011-12-07 | Amylin Pharmaceuticals Inc. | GIP analog and hybrid polypeptides with selectable properties |
WO2006136374A2 (en) | 2005-06-20 | 2006-12-28 | Develogen Aktiengesellschaft | Use of gip and/or vitamin d3 analogues thereof for enhancing stem or progenitor cell differentiation into insulin producing cells |
US20080015265A1 (en) | 2006-07-11 | 2008-01-17 | Byron Rubin | Methods of treating obesity using satiety factors |
AU2007284365A1 (en) | 2006-08-17 | 2008-02-21 | Amylin Pharmaceuticals, Inc. | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
JO2945B1 (en) | 2006-09-13 | 2016-03-15 | سميث كلاين بيتشام كوربوريشن | Methods of giving prolonged hypoglycemic agents |
EP1972349A1 (en) * | 2007-03-21 | 2008-09-24 | Biocompatibles UK Limited | GLP-1 fusion peptides conjugated to polymer(s), their production and use |
US8710002B2 (en) | 2007-11-23 | 2014-04-29 | Michael Rothkopf | Methods of enhancing diabetes resolution |
PL2300035T3 (pl) | 2008-06-17 | 2016-04-29 | Univ Indiana Res & Tech Corp | Mieszani agoniści na bazie GIP do leczenia zaburzeń metabolicznych i otyłości |
KR20110043689A (ko) * | 2008-08-07 | 2011-04-27 | 입센 파마 에스.에이.에스 | N-말단이 변형된 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드(gip)의 유사체 |
DK2373681T3 (en) | 2008-12-10 | 2017-04-24 | Glaxosmithkline Llc | PHARMACEUTICAL COMPOSITIONS OF ALBIGLUTID |
KR20120087875A (ko) * | 2009-06-16 | 2012-08-07 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | Gip 수용체-활성 글루카곤 화합물 |
WO2011002066A1 (ja) | 2009-07-02 | 2011-01-06 | 武田薬品工業株式会社 | ペプチド及びその用途 |
IN2012DN06437A (lt) | 2010-01-27 | 2015-10-09 | Univ Indiana Res & Tech Corp | |
AR080592A1 (es) | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
MX2013007327A (es) | 2010-12-22 | 2014-01-08 | Marcadia Biotech Inc | Metodos para tratar transtornos metabolicos y obesidad con peptidos basados en glucagon activos para el receptor de gip y glp-1. |
EP2694095B1 (en) | 2011-04-05 | 2018-03-07 | Longevity Biotech, Inc. | Compositions comprising glucagon analogs and methods of making and using the same |
KR102002783B1 (ko) | 2011-06-10 | 2019-07-24 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | 포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용 |
PL2718316T3 (pl) | 2011-06-10 | 2020-06-29 | Novo Nordisk A/S | Polipeptydy |
US20130090285A1 (en) | 2011-06-27 | 2013-04-11 | Phasebio Pharmaceuticals, Inc. | Methods of treatment with glp-1 receptor agonists |
WO2013037690A1 (en) | 2011-09-06 | 2013-03-21 | Novo Nordisk A/S | Glp-1 derivatives |
CA2862516C (en) | 2012-03-27 | 2023-02-14 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
TR201815338T4 (tr) | 2012-05-03 | 2018-11-21 | Zealand Pharma As | Gıp-glp-1 dual agonist bileşikleri ve yöntemler. |
CN104519902B (zh) | 2012-05-08 | 2017-10-27 | 诺和诺德股份有限公司 | 双酰化glp‑1衍生物 |
US20150182461A1 (en) | 2012-06-19 | 2015-07-02 | Massachussets Institute Of Technology | Mass Production and Size Control of Nanoparticles Through Controlled Microvortices |
PE20150863A1 (es) | 2012-06-21 | 2015-06-11 | Univ Indiana Res & Tech Corp | Analogos de glucagon que exhiben actividad de receptor de gip |
CA2877358A1 (en) | 2012-06-21 | 2013-12-27 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
EP2935318A1 (en) | 2012-12-19 | 2015-10-28 | Novo Nordisk A/S | Novel glp-1 receptor agonists with cholesterol efflux activity |
HUE038748T2 (hu) | 2012-12-21 | 2018-11-28 | Sanofi Sa | Exendin-4 származékok, mint duális GLP1/GIP- vagy trigonális GLP1/GIP/glukagon-agonisták |
EP2968581A1 (en) | 2013-03-14 | 2016-01-20 | Medimmune Limited | Pegylated glucagon and glp-1 co-agonists for the treatment of obesity |
MA38472B1 (fr) | 2013-05-28 | 2018-09-28 | Takeda Pharmaceuticals Co | Composé peptidique |
MX369770B (es) | 2013-11-06 | 2019-11-21 | Zealand Pharma As | Compuestos agonistas triples de glucagón-glp-1-gip. |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
JP2018012644A (ja) | 2014-11-26 | 2018-01-25 | 武田薬品工業株式会社 | ペプチド化合物 |
-
2014
- 2014-05-27 MA MA38472A patent/MA38472B1/fr unknown
- 2014-05-27 TW TW103118374A patent/TWI638831B/zh active
- 2014-05-27 SG SG11201507934PA patent/SG11201507934PA/en unknown
- 2014-05-27 HR HRP20212014TT patent/HRP20212014T1/hr unknown
- 2014-05-27 PT PT147299762T patent/PT3004155T/pt unknown
- 2014-05-27 KR KR1020157032121A patent/KR102229051B1/ko active IP Right Grant
- 2014-05-27 MX MX2015015464A patent/MX2015015464A/es active IP Right Grant
- 2014-05-27 UA UAA201510946A patent/UA118558C2/uk unknown
- 2014-05-27 EP EP14729976.2A patent/EP3004155B1/en active Active
- 2014-05-27 LT LTEPPCT/JP2014/002772T patent/LT3004155T/lt unknown
- 2014-05-27 ES ES14729976T patent/ES2900744T3/es active Active
- 2014-05-27 US US14/287,514 patent/US9200051B2/en active Active
- 2014-05-27 UY UY0001035589A patent/UY35589A/es not_active Application Discontinuation
- 2014-05-27 DK DK14729976.2T patent/DK3004155T3/da active
- 2014-05-27 SI SI201431933T patent/SI3004155T1/sl unknown
- 2014-05-27 PL PL14729976T patent/PL3004155T3/pl unknown
- 2014-05-27 AR ARP140102090A patent/AR096440A1/es unknown
- 2014-05-27 CN CN201480026613.0A patent/CN105209485B/zh active Active
- 2014-05-27 PE PE2015002124A patent/PE20151770A1/es unknown
- 2014-05-27 TN TN2015000451A patent/TN2015000451A1/en unknown
- 2014-05-27 AP AP2015008781A patent/AP2015008781A0/xx unknown
- 2014-05-27 GE GEAP201413984A patent/GEP201706762B/en unknown
- 2014-05-27 JP JP2015555470A patent/JP6429799B2/ja active Active
- 2014-05-27 WO PCT/JP2014/002772 patent/WO2014192284A1/en active Application Filing
- 2014-05-27 HU HUE14729976A patent/HUE057361T2/hu unknown
- 2014-05-27 AU AU2014272500A patent/AU2014272500B2/en active Active
- 2014-05-27 US US14/780,579 patent/US10087229B2/en active Active
- 2014-05-27 EA EA201591891A patent/EA035813B1/ru unknown
- 2014-05-27 EA EA202090593A patent/EA202090593A3/ru unknown
- 2014-05-27 MY MYPI2015703438A patent/MY172744A/en unknown
- 2014-05-27 CA CA2908581A patent/CA2908581C/en active Active
-
2015
- 2015-10-11 IL IL242005A patent/IL242005B/en active IP Right Grant
- 2015-10-13 CL CL2015003031A patent/CL2015003031A1/es unknown
- 2015-10-14 PH PH12015502391A patent/PH12015502391A1/en unknown
- 2015-10-15 DO DO2015000261A patent/DOP2015000261A/es unknown
- 2015-10-21 EC ECIEPI201544389A patent/ECSP15044389A/es unknown
- 2015-11-06 MX MX2019010531A patent/MX2019010531A/es unknown
-
2016
- 2016-04-28 HK HK16104856.7A patent/HK1216757A1/zh unknown
-
2018
- 2018-06-12 JP JP2018111494A patent/JP6570705B2/ja active Active
-
2021
- 2021-12-15 CY CY20211101100T patent/CY1124790T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1216757A1 (zh) | 肽化合物 | |
EP2960234A4 (en) | INHIBITING COMPOUND Trk | |
GB201302368D0 (en) | Compound | |
HRP20180452T1 (hr) | Peptidi | |
EP2982674A4 (en) | PYRIDINYLPYRAZOLOCHINOLINVERBINDUNG | |
PL3061771T3 (pl) | Nowy peptyd o czterech połączonych epitopach dla ctl | |
HK1211596A1 (en) | Peptide | |
EP2947066A4 (en) | PHENOXYALKYLAMINVERBINDUNG | |
HK1211595A1 (en) | Peptide | |
HK1198769A1 (en) | Novel peptide | |
GB201315130D0 (en) | Peptides | |
GB201307331D0 (en) | Compound | |
GB201319776D0 (en) | Compound | |
GB201316660D0 (en) | Peptides | |
GB201315772D0 (en) | Compound | |
GB201300381D0 (en) | Peptides | |
GB201305634D0 (en) | Compound | |
GB201304250D0 (en) | Compound | |
GB201301585D0 (en) | Compound |